Exploring the revolutionary potential of MXene nanoparticles in breast Cancer therapy: A review of applications and future prospects

Amani, AM; Tayebi, L; Vafa, E; Bazarganlari, R; Abbasi, M; Vaez, A; Kamyab, H; Rajendran, S; Azizli, MJ

Keywords: breast cancer, photothermal therapy, theranostics, MXene

Abstract

Breast cancer is a leading cause of cancer-related deaths in women worldwide. Early detection and accurate diagnosis are crucial for successful treatment and improving patient outcomes. Nanoparticles, such as MXenes, have emerged as a promising tool for various breast cancer applications due to their unique properties. MXenes possess a high surface area and excellent biocompatibility, and can be engineered to enhance targeting ability, as well as mechanical, electrochemical, and optical properties. This review article explores the potential of MXenes in breast cancer detection and treatment, including miRNA detection, MRI-guided photothermal therapy, combined therapy, and immunotherapy. MXenes can be used for miRNA detection, which has shown promise as a biomarker for breast cancer. MXenes can also be used for MRI-guided photothermal therapy, where they can absorb light and convert it into heat to destroy cancer cells. Additionally, MXenes can be used in combination therapy with other drugs to enhance their efficacy. MXenes can also be used for immunotherapy by enhancing the immune response against cancer cells. The article also discusses the future prospects of MXenes in breast cancer research and their cytotoxicity effects. The use of MXenes in breast cancer research is a novel approach with great potential for improving patient outcomes. © 2025 Elsevier B.V.

Más información

Título según WOS: Exploring the revolutionary potential of MXene nanoparticles in breast Cancer therapy: A review of applications and future prospects
Título según SCOPUS: Exploring the revolutionary potential of MXene nanoparticles in breast Cancer therapy: A review of applications and future prospects
Título de la Revista: International Immunopharmacology
Volumen: 152
Editorial: Elsevier B.V.
Fecha de publicación: 2025
Idioma: English
DOI:

10.1016/j.intimp.2025.114411

Notas: ISI, SCOPUS